Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics152
Neuroscience & CNS90
Immunology & Autoimmune80
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms149
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $1.0t | $1153.79 | +0.1% | 1.8M |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.7t | $270.02 | -0.1% | 6.3M |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $462.5b | $264.50 | -0.0% | 3.2M |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $375.8b | $146.57 | -0.4% | 6.5M |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $250.7b | $167.15 | +0.3% | 2.6M |
 AMGN | Amgen Inc | Rare Disease TherapeuticsImmunology & Autoimmune | $239.4b | $385.38 | +1.5% | 3.0M |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $228.7b | $652.29 | -1.1% | 2.3M |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $185.5b | $149.90 | -0.6% | 6.8M |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $164.2b | $27.61 | -0.1% | 23.9M |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $141.4b | $506.78 | -1.6% | 987.0K |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $138.2b | $62.92 | +0.1% | 9.3M |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $86.8b | $784.57 | -0.6% | 495.9K |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $59.4b | $153.90 | -2.6% | 9.2M |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $43.4b | $261.31 | -1.1% | 2.0M |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $42.7b | $158.63 | +2.3% | 1.8M |
 WAT | Waters Corp | Clinical-Stage Platforms | $40.6b | $423.39 | -1.9% | 463.6K |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $35.8b | $239.62 | -2.4% | 1.4M |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $32.9b | $217.00 | -1.5% | 880.0K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $28.4b | $58.70 | -0.9% | 1.7M |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $27.7b | $120.48 | -3.2% | 2.1M |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $26.1b | $125.91 | -1.8% | 1.3M |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $24.9b | $40.33 | -0.4% | 7.6M |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $24.1b | $362.14 | -1.2% | 377.6K |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $21.0b | $494.73 | -0.5% | 373.2K |
 ASND | Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $17.5b | $238.46 | -0.9% | 703.0K |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $16.6b | $576.94 | -0.4% | 166.9K |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $16.1b | $146.57 | -3.7% | 1.1M |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $15.9b | $237.74 | -1.3% | 503.6K |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $15.0b | $66.64 | -1.1% | 1.9M |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $14.6b | $144.71 | -2.2% | 2.1M |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $13.9b | $277.84 | -1.3% | 603.2K |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $13.7b | $17.79 | +0.6% | 3.5M |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $13.0b | $63.90 | -1.8% | 1.6M |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $12.5b | $531.48 | -0.6% | 152.3K |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $12.4b | $113.00 | +2.6% | 8.3M |
 ICLR | Icon Plc | Clinical-Stage Platforms | $12.3b | $164.11 | -3.4% | 911.9K |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $12.1b | $66.97 | -1.7% | 1.8M |
 CORT | Corcept Therapeutics Inc. | Rare Disease Therapeutics | $11.9b | $111.28 | -3.9% | 2.0M |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $11.4b | $72.28 | -0.0% | 2.9M |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $11.0b | $207.16 | -3.0% | 444.3K |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $10.9b | $340.88 | -0.6% | 208.4K |
 APGE | Apogee Therapeutics, Inc. Common Stock | Immunology & Autoimmune | $10.2b | $135.09 | 0.0% | N/A |
 IONS | Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $10.2b | $44.59 | -5.0% | 3.4M |
 CYTK | Cytokinetics Inc. | Rare Disease TherapeuticsNeuroscience & CNS | $10.0b | $68.83 | -1.7% | 1.3M |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $9.9b | $297.79 | -3.7% | 572.7K |
 AVTR | Avantor, Inc. | Clinical-Stage Platforms | $9.9b | $15.52 | -2.2% | 9.2M |
 KYMR | Kymera Therapeutics, Inc. Common Stock | Clinical-Stage Platforms | $9.9b | $117.75 | -0.6% | 542.4K |
 PTGX | Protagonist Therapeutics, Inc | Metabolic & CardiometabolicImmunology & Autoimmune | $9.6b | $143.03 | -0.5% | 477.5K |
 RGEN | Repligen Corp | Clinical-Stage Platforms | $9.6b | $176.90 | -0.7% | 675.3K |
 PCVX | Vaxcyte, Inc. Common Stock | Infectious Disease & Vaccines | $9.1b | $58.10 | -3.7% | 1.3M |